All In Biotech

Drug Trial Radar · NCT04299893

Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)

Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Nov 30, 2020

Primary completion

Sep 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Bernardino Clavo, MD, PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Servicio Canario de Salud; Instituto de Salud Carlos III; Red de Investigación en Servicios de Salud en Enfermedades Crónicas; Fundación DISA, Spain; Fundación Española del Dolor (FED); Council of Gran Canaria
First posted
Mar 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy

Conditions

  • Chemotherapy-induced Peripheral Neuropathy
  • Pain, Neuropathic
  • Pain Syndrome

Interventions

  • OzoneDrug

    Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.

  • OxygenDrug

    Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in "Average pain" according to the Brief Pain Inventory-Short Form (BPI-SF) (at the end of ozone therapy)Time frame: 16 weeks
  2. Direct Hospital Cost (at the end of ozone therapy)Time frame: 16 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Complejo Hospitalario Materno Insular

    Las Palmas de Gran Canaria, Las Palmas, Spain · Recruiting

  • Hospital Universitario de Gran Canaria Dr. Negrín

    Las Palmas de Gran Canaria, Las Palmas, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.